Evidence map›Paper›PMID 26674605›Full record

ArticleMolecular pharmaceutics2016

Development of a Unified Dissolution and Precipitation Model and Its Use for the Prediction of Oral Drug Absorption.

Paulina Jakubiak, Björn Wagner, Hans Peter Grimm, Jeannine Petrig-Schaffland, Franz Schuler, Rubén Alvarez-Sánchez

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular pharmaceutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Paulina JakubiakRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel , Basel, Switzerland.
Björn WagnerRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel , Basel, Switzerland.
Hans Peter GrimmRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel , Basel, Switzerland.
Jeannine Petrig-SchafflandRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel , Basel, Switzerland.
Franz SchulerRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel , Basel, Switzerland.
Rubén Alvarez-SánchezRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel , Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug absorption is a complex process involving dissolution and precipitation, along with other kinetic processes. The purpose of this work was to (1) establish an in vitro methodology to study dissolution and precipitation in early stages of drug development where low compound consumption and high throughput are necessary, (2) develop a mathematical model for a mechanistic explanation of generated in vitro dissolution and precipitation data, and (3) extrapolate in vitro data to in vivo situations using physiologically based models to predict oral drug absorption. Small-scale pH-shift studies were performed in biorelevant media to monitor the precipitation of a set of poorly soluble weak bases. After developing a dissolution-precipitation model from this data, it was integrated into a simplified, physiologically based absorption model to predict clinical pharmacokinetic profiles. The model helped explain the consequences of supersaturation behavior of compounds. The predicted human pharmacokinetic profiles closely aligned with the observed clinical data. In summary, we describe a novel approach combining experimental dissolution/precipitation methodology with a mechanistic model for the prediction of human drug absorption kinetics. The approach unifies the dissolution and precipitation theories and enables accurate predictions of in vivo oral absorption by means of physiologically based modeling.

Indexed as

Models, BiologicalAdministration, OralComputer SimulationErlotinib HydrochlorideGastrointestinal AbsorptionHumansKineticsPermeabilityTissue DistributionErlotinib HydrochlorideBCSbiorelevant mediadissolutionFaSSIFFeSSIFformulation testingin vitro−in vivo correlationoral absorptionphysiologically based pharmacokinetic modelingprecipitationsimulated intestinal fluidssolubilitysupersaturationweak bases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.